The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis
Open accessAbstract
Background Reliable prognostic factors are lacking for multiple sclerosis (MS). Gadolinium enhancement in magnetic resonance imaging (MRI) of the brain detects with high sensitivity disturbance of the blood-brain barrier, an early event in the development of inflammatory lesions in MS. To investigate the prognostic value of gadolinium-enhanced MRI, we did a meta-analysis of longitudinal MRI studies. Methods From the members of MAGNIMS (European Magnetic Resonance Network in Multiple Sclerosis) and additional centres in the USA, we collected data from five natural-course studies and four placebo groups of clinical trials completed between 1992 and 1995. We included a total of 307 patients, 237 with relapsing disease course and 70 with secondary progressive disease course. We investigated by regression analysis the relation between initial count of gadolinium-enhancing lesions and subsequent worsening of disability or impairment as measured by the expanded disability status scale (EDSS) and relapse rate. Findings The relapse rate in the first year was predicted with moderate ability by the mean number of gadolinium-enhancing lesions in monthly scans during the first 6 months (relative risk per five lesions 1.13, p=0.023). The predictive value of the number of gadolinium-enhancing lesions in one baseline scan was less strong. The best predictor for relapse rate was the variation (SD) of lesion counts in the first six monthly scans which allowed an estimate of relapse in the firs…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Conventional T2-weighted MRI (cMRI) largely fails to predict the degree of patients' disability.”
From Diffusion tensor imaging of post mortem multiple sclerosis brain (2007) · cites this paper as Kappos et al., 1999
In the citing paper
“The inability of cMRI to reflect MS pathology in more detail may be one of the major reasons why the correlation between cMRI measures and disability is only modest (Kappos et al., 1999; Brex et al., 2002).”
From Diffusion tensor imaging of post mortem multiple sclerosis brain (2007) · cites this paper as Kappos et al., 1999
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
Defining the clinical course of multiple sclerosis
LUBLIN, F. D., & Reingold, S. C. (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,762
Schuenemeyer, J. H., McCullagh, P. J., & Nelder, J. A. (1992) · Technometrics · doi:10.2307/1269238 · Cited by 2,702
Interferon beta‐lb in the treatment of multiple sclerosis
The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1995) · Neurology · doi:10.1212/wnl.45.7.1277 · Cited by 971
The role of magnetic resonance techniques in understanding and managing multiple sclerosis
Miller, D. (1998) · Brain · doi:10.1093/brain/121.1.3 · Cited by 553
Self-citationBrück, W., Bitsch, A., Kolenda, H., Brück, Y., Stiefel, M., & Lassmann, H. (1997) · Annals of Neurology · doi:10.1002/ana.410420515 · Cited by 520
The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up
O’Riordan, J. I. (1998) · Brain · doi:10.1093/brain/121.3.495 · Cited by 480
Truyen, L., van Waesberghe, J. H. T. M., van Walderveen, M. A. A., van Oosten, B. W., Polman, C. H., Hommes, O. R., Adèr, H. J., & Barkhof, F. (1996) · Neurology · doi:10.1212/wnl.47.6.1469 · Cited by 461
Self-citationKatz, D., Taubenberger, J. K., Cannella, B., McFarlin, D. E., Raine, C. S., & McFarland, H. F. (1993) · Annals of Neurology · doi:10.1002/ana.410340507 · Cited by 387
Research works printed but not linked: 2
- Hohol, 1997, Roquinimex (Linomide) treatment in secondary progressive and relapsing remitting multiple sclerosis: results from 48 week randomized, double-blind, placebo-controlled pilot studies, Neurology, 48, A174
- Kappos, 1996, the 15± Deoxyspergualine (DSG) in the treatment of active multiple sclerosis: final analysis of the European multicenter study, Neurology, 46, A410
Cited by
Sorted by citations
Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines, Goodin, D. S., Frohman, E. M., Garmany, G. P., Halper, J., Likosky, W., LUBLIN, F. D., Silberberg, D. H., Stuart, W. H., & van den Noort, S. (2002) · Neurology · doi:10.1212/wnl.58.2.169 · Cited by 797
Molecular physiology and pathophysiology of tight junctions in the blood–brain barrier
Huber, J. D., Egleton, R. D., & Davis, T. P. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)02004-x · Cited by 790
Comi, G., Filippi, M., & Wolinsky, J. S. (2001) · PubMed · Cited by 688
Self-citationComi, G., Filippi, M., Wolinsky, J. S., & European/Canadian Glatiramer Acetate Study Group (2001) · Annals of Neurology · doi:10.1002/ana.64 · Cited by 768
Self-citationBlood neurofilament light chain as a biomarker of MS disease activity and treatment response
Kühle, J., Kropshofer, H., Häring, D. A., Kundu, U., Meinert, R., Barro, C., Dahlke, F., Tomic, D., Leppert, D., & Kappos, L. (2019) · Neurology · doi:10.1212/wnl.0000000000007032 · Cited by 568
Self-citation
Metadata
- Authors
- Kappos, L., Moeri, D., Radue, E. W., Schoetzau, A., Schweikert, K., Barkhof, F., Miller, D., Guttmann, C. R., Weiner, H. L., Gasperini, C., & Filippi, M.
- Affiliations
- University Hospital of Basel (CH)
- Vrije Universiteit Amsterdam (NL)
- UCL Queen Square Institute of Neurology (GB)
- Brigham and Women's Hospital (US)
- Sapienza University of Rome (IT)
- University of Milan (IT)
- Corresponding author
- Kappos, Ludwig
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 1999-03
- Volume
- 353
- Issue
- 9157
- Pages
- 964-969
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2141185335
- Cited by
- 499
- References
- 34
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 6 · 2023: 10 · 2022: 10 · 2021: 13 · 2020: 10 · 2019: 11 · 2018: 9 · 2017: 12 · 2016: 18 · 2015: 26 · 2014: 19 · 2013: 18 · 2012: 9
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Open access
- green
- research.vumc.nl
- Licence
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
- Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- Multiple Sclerosis Society
- Schweizerische Multiple Sklerose Gesellschaft
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
- Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
- Keywords
- multiple sclerosis, gadolinium-enhancing lesions, relapse rate, disability progression, Expanded Disability Status Scale, prognostic factors, blood-brain barrier disruption, secondary progressive multiple sclerosis, relapsing-remitting multiple sclerosis, natural history of disease, disease-modifying therapy response, treatment response prediction, relapse
- MeSH terms
- Adolescent, Adult, Blood-Brain Barrier, Brain, Clinical Trials as Topic, Contrast Media, Female, Forecasting, Gadolinium, Persons with Disabilities, Disabled Persons, Humans, Longitudinal Studies, Magnetic Resonance Imaging, Male, Middle Aged, Multiple Sclerosis, Predictive Value of Tests, Prognosis, Recurrence, Regression Analysis, Risk Factors, Multicenter Studies as Topic, Odds Ratio, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
